Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far
AbstractDespite advances in the management of type 2 diabetes mellitus (T2DM), one-third of patients with diabetes do not achieve the desired glycemic goal. Considering this inadequacy, many agents that activate glucokinase have been investigated over the last two decades but were withdrawn before submission for marketing permission. Dorzagliatin is the first glucokinase activator that has been granted approval for T2DM, only in China. As overstimulation of glucokinase is linked with pathophysiological disturbances such as fatty liver and cardiovascular issues and a loss of therapeutic efficacy with time. This review aims ...
Source: Clinical Drug Investigation - March 9, 2024 Category: Drugs & Pharmacology Source Type: research

Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan
ConclusionsThese results suggest that upadacitinib 30 mg can ameliorate rash and pruritus insufficiently improved by upadacitinib 15 mg, and that the dose increase to 30 mg may be considered as a  treatment option for patients with atopic dermatitis with a limited response to upadacitinib 15 mg. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 6, 2024 Category: Drugs & Pharmacology Source Type: research

Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 2, 2024 Category: Drugs & Pharmacology Source Type: research

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients
ConclusionsThe results support the use of 180  mg RBP-7000 in schizophrenic patients stable on 6 mg/day oral risperidone and a second injection site in the upper arm.Trial RegistrationClinicalTrials.gov identifier: NCT03978832. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 22, 2024 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
ConclusionsAtogepant and rimegepant were both unable to meet generally accepted cost-effectiveness thresholds< 150,0000/QALY. Additional studies are needed to better guide decision making regarding oral CGRPs ’ place in therapy. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 21, 2024 Category: Drugs & Pharmacology Source Type: research

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
ConclusionsSotrovimab demonstrated clinical effectiveness in preventing severe outcomes (hospitalisation, mortality) in the period 27 September 2021 –30 April 2022, which included Delta and Omicron BA.1 variants and an early surge of Omicron BA.2 variant. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 20, 2024 Category: Drugs & Pharmacology Source Type: research

Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database
ConclusionThis study yielded three key findings. Firstly, EGFR-TKIs seem to exhibit prothrombotic effects, elevating the risk of TEEs. Secondly, the clinical outcomes of TEEs associated with EGFR-TKIs were poor. Thirdly, most TEEs occurred within the initial 3 months, and fatal cases occurred earlier than non-fatal cases. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 20, 2024 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 19, 2024 Category: Drugs & Pharmacology Source Type: research

Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center
ConclusionIVP valproate administration may be considered safe, allowing for more optimal clinical and operational outcomes in the acute care setting. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 16, 2024 Category: Drugs & Pharmacology Source Type: research

Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia
ConclusionHyperuricemia was independently related to an increased risk of all-cause and cardiovascular death in patients with ACS undergoing PCI. At 1-year follow-up, there were no significant differences between ticagrelor and clopidogrel concerning all-cause and cardiovascular death in patients with hyperuricemia. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 7, 2024 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
ConclusionsCamrelizumab plus rivoceranib was more cost effective than sorafenib as first-line therapy for unresectable HCC in the Chinese setting. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 1, 2024 Category: Drugs & Pharmacology Source Type: research

Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF- α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance
ConclusionsWe conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor- α inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - January 31, 2024 Category: Drugs & Pharmacology Source Type: research

Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care
AbstractThe selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters. Factors influencing inhaler choice include measures such as f...
Source: Clinical Drug Investigation - January 10, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Association Between Antidiabetic Drugs and Delirium: A Study Based on the Adverse Drug Event Reporting Database in Japan
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - January 10, 2024 Category: Drugs & Pharmacology Source Type: research

A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate –Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis
ConclusionThe fixed-dose combination of once-daily fluticasone furoate and oxymetazoline hydrochloride nasal spray 27.5/50  mcg was effective in relieving the nasal congestion and reduction of TNSS, TOSS and TSS in patients suffering from AR. The combination was safe and well tolerated with no rebound congestion throughout the treatment period. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - January 9, 2024 Category: Drugs & Pharmacology Source Type: research